CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 111 enrolled
Drug / intervention
Aripiprazoledrug
Likely dose
Aripiprazole 24mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00392197
NCT00392197Phase 4Completed
CompareCT.gov

Post Marketing Clinical Study of Aripiprazole in Patients With Schizophrenia - Effects on Glucose Metabolism-

Otsuka Pharmaceutical Co., Ltd.·interventional·Posted Oct 25, 2006·Updated Feb 12, 2014

In Brief

A Phase 4 clinical trial evaluating Aripiprazole for Schizophrenia. Completed, enrolled 111 participants across 5 sites.

Detailed Summary

The objective of this study is to examine the effects of aripiprazole on glucose metabolism in schizophrenic patients without hyperglycemia and diabetes mellitus or any history thereof.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesJapan
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 25, 2006
Enrollment StartNov 1, 2006
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 19.7 years ago

Interventions

Aripiprazoledrug

1 or 2 times a day, p.o., 6 - 24mg a day